IBI3003 is a novel trispecific antibody targeting GPRC5D, BCMA and CD3 simultaneously. Its dual-targeting design against BCMA and GPRC5 aims to overcome single antigen escape in multiple myeloma (MM).
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint ...
An announcement from Perspective Therapeutics ( ($CATX) ) is now available. On December 1, 2025, Perspective Therapeutics updated its corporate ...
For those new to Karooooo, we operate a SaaS platform for connected vehicles and mobile assets that enables businesses to ...
Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant ...
Get the latest on Vera Therapeutics, Inc., FDA progress for atacicept, and IgA nephropathy drug competition. Click to what to ...
Rusfertide was generally well-tolerated through 52 Weeks of treatment. The most common treatment-emergent adverse events (AE) in rusfertide-treated patients were injection site reactions (47.4%), ...
5d
Option Care Health, Inc. (OPCH) Presents at Bank of America Leveraged Finance Conference Transcript
Bank of America Leveraged Finance Conference December 2, 2025 10:50 AM ESTCompany ParticipantsNicole Maggio - Senior ...
WISN 12 News on MSN
Prada Group says it has purchased fashion rival Versace in a deal worth nearly $1.4 billion
The Prada Group announced Tuesday that it has officially purchased Milan fashion rival Versace in a 1.25 billion euro (nearly ...
MPACT’s VivoCity reported positive rental reversion of 14.1% in 2QFY2026 ended Sept 30. UOBKH thinks MPACT will be acquired ...
The U. of Tulsa was a commuter campus that tried — and tried again — to become a regional powerhouse. Now it’s drowning in ...
Q4 2025 guidance -- Projected total revenue of $371 million to $377 million; subscription revenue of $258 million to $261 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback